Trastuzumab-Induced Cardiomyopathy

Journal of Cardiac Failure

Volumn 14, Issue 5, 2008, Pages 437-444

  Guglin, Maya ^a   Cutro, Raymond ^a   Mishkin, Joseph D ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIRUBICIN; HUMAN MONOCLONAL ANTIBODY; LAPATINIB; NEU DIFFERENTIATION FACTOR; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ADVANCED CANCER; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CELL; CHEMOTHERAPY; CLINICAL FEATURE; CYTOTOXICITY; DISEASE PREDISPOSITION; DRUG DOSE ESCALATION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HISTOLOGY; HUMAN; IMMUNE SYSTEM; LEG EDEMA; LUNG EDEMA; MEDLINE; METASTASIS; MULTIPLE CYCLE TREATMENT; MUSCLE CELL; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; SURVIVAL; SYSTOLIC DYSFUNCTION; TREATMENT PLANNING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; FEMALE; HEART FAILURE; HUMANS; MUSCLE CELLS; NEUREGULIN-1; RECEPTOR, ERBB-2; RISK FACTORS; STRESS, PSYCHOLOGICAL; VENTRICULAR FUNCTION, LEFT;

EID: 44349121910     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.02.002     Document Type: Review

References (38)

1. Klein P.M., and Dybdal N. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol 30 5 Suppl. 16 (2003) 49-53
2. Seidman A., Hudis C., Pierri M.K., Shak S., Paton V., Ashby M., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 (2002) 1215-1221
3. Perez E.A., and Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22 (2004) 322-329
4. Feldman A.M., Lorell B.H., and Reis S.E. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102 (2000) 272-274
5. Noma T., Lemaire A., Naga Prasad S.V., Barki-Harrington L., Tilley D.G., Chen J., et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117 (2007) 2445-2458
6. Force T., Krause D.S., and Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7 (2007) 332-344
7. Guarneri V., Lenihan D.J., Valero V., Durand J.B., Broglio K., Hess K.R., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24 (2006) 4107-4115
8. Grazette L.P., Boecker W., Matsui T., Semigran M., Force T.L., Hajjar R.J., et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for Herceptin-induced cardiomyopathy. J Am Coll Cardiol 44 (2004) 2231-2238
9. Ewer M.S., Vooletich M.T., Durand J.B., Woods M.L., Davis J.R., Valero V., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005) 7820-7826
10. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8 (2002) 459-465
11. Ozcelik C., Erdmann B., Pilz B., Wettschureck N., Britsch S., Hubner N., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99 (2002) 8880-8885
12. Sawyer D.B., Zuppinger C., Miller T.A., Eppenberger H.M., and Suter T.M. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105 (2002) 1551-1554
13. Burris III H., Yardley D., Jones S., Houston G., Broome C., Thompson D., et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22 (2004) 1621-1629
14. Perik P.J., de Vries E.G., Gietema J.A., van der Graaf W.T., Smilde T.D., Sleijfer D.T., et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail 9 (2007) 173-177
15. Bianchi G., Albanell J., Eiermann W., Vitali G., Borquez D., Vigano L., et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 9 16 Pt 1 (2003) 5944-5951
16. Burstein H.J., Kuter I., Campos S.M., Gelman R.S., Tribou L., Parker L.M., et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19 (2001) 2722-2730
17. Seidman A.D., Fornier M.N., Esteva F.J., Tan L., Kaptain S., Bach A., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19 (2001) 2587-2595
18. Esteva F.J., Valero V., Booser D., Guerra L.T., Murray J.L., Pusztai L., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 1800-1808
19. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
20. Bengala C., Zamagni C., Pedrazzoli P., Matteucci P., Ballestrero A., Da Prada G., et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 94 (2006) 1016-1020
21. Kelly H., Kimmick G., Dees E.C., Collichio F., Gatti L., Sawyer L., et al. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 7 (2006) 237-243
22. Pegram M.D., Pienkowski T., Northfelt D.W., Eiermann W., Patel R., Fumoleau P., et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96 (2004) 759-769
23. Papaldo P., Fabi A., Ferretti G., Mottolese M., Cianciulli A.M., Di Cocco B., et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 17 (2006) 630-636
24. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
25. Venturini M., Bighin C., Monfardini S., Cappuzzo F., Olmeo N., Durando A., et al. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 95 (2006) 45-53
26. Smith K.L., Dang C., and Seidman A.D. Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf 5 (2006) 619-629
27. Tripathy D., Seidman A., Keefe D., Hudis C., Paton V., and Lieberman G. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 5 (2004) 293-298
28. Gori S., Colozza M., Mosconi A.M., Franceschi E., Basurto C., Cherubini R., et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 90 (2004) 36-40
29. Untch M., Himsl I., Kahlert S., Lueck H.J., Eidtmann H., Du Bois A., et al. Anthracycline and trastuzumab in breast cancer treatment. Oncology (Williston Park) 18 14 Suppl. 14 (2004) 59-64
30. Tan-Chiu E., Yothers G., Romond E., Geyer Jr. C.E., Ewer M., Keefe D., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 (2005) 7811-7819
31. Knobloch K., Tepe J., Lichtinghagen R., Luck H.J., and Vogt P.M. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int J Cardiol (2007 Mar 30) [Epub ahead of print]
32. Lenihan D.J., MM, Baysinger K.B., Adorno C.L., Warneke C.L., Steinert D., Fayad L., et al. Superior detection of cardiotoxicity during chemotherapy using biomarkers. J Card Fail 13 6 Suppl. 2 (2007) S151
33. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61 Suppl 2 (2001) 58-66
34. Leyland-Jones B., Gelmon K., Ayoub J.P., Arnold A., Verma S., Dias R., et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21 (2003) 3965-3971
35. Burstein H.J., Harris L.N., Marcom P.K., Lambert-Falls R., Havlin K., Overmoyer B., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21 (2003) 2889-2895
36. Untch M., Eidtmann H., du Bois A., Meerpohl H.G., Thomssen C., Ebert A., et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 40 (2004) 988-997
37. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
38. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36